Avenzo Therapeutics and Dualitybio Announce Exclusive Global License for Potential Best-in-Class Egfr/Her3 Antibody-Drug Conjugate
Avenzo Therapeutics和Dualitybio宣布独家全球货币许可,开发潜在最佳EGFR/Her3抗体药物偶联物
Avenzo Therapeutics and Dualitybio Announce Exclusive Global License for Potential Best-in-Class Egfr/Her3 Antibody-Drug Conjugate
Avenzo Therapeutics和Dualitybio宣布独家全球货币许可,开发潜在最佳EGFR/Her3抗体药物偶联物
使用浏览器的分享功能,分享给你的好友吧